Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Results of Aptosyn trial show inhibition of rise in PSA levels in prostate cancer patients

Nov. 19, 1999

Ribozyme and Chiron initiate phase I/II studies of Angiozyme

Nov. 18, 1999

Somatostatin receptor ligands synthesized and tested at Takeda

Nov. 18, 1999

ImmunoGen options antibody from Duke and Johns Hopkins

Nov. 18, 1999

RPR/INGN-201 + radiotherapy provides supraadditive effects in prostate cancer xenograft models

Nov. 17, 1999

Lorus files IND seeking clearance for phase I/II clinical trials of GTI-2040

Nov. 17, 1999

Foscan receives orphan drug designation in U.S.; MAA accepted in E.U.

Nov. 17, 1999

Pharmaceutical agents useful as vitronectin antagonists and methods of use

Nov. 17, 1999

Kinase inhibitors developed at Boehringer Ingelheim as potential anticancer agents

Nov. 17, 1999

Ontogen completes phase I multidose oral study of MDR compound

Nov. 17, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Recombinant vaccine inhibits HBV-associated HCC growth
BioWorld Science
Chronic liver disease and hepatocellular carcinoma (HCC) associated with chronic hepatitis B virus (HBV) are serious health problems in highly endemic areas....